LBIO News 8.6500 Lion Biotechnologies Inc. (LBIO)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lion Biotechnologies Inc. (LBIO) 8.6500 $LBIO

Lion Biotechnologies' Lead Program With National Cancer Institute Demonstrates Positive Results in Patients With Stage 4 Metastatic Melanoma
GlobeNewswire - Mon Apr 07, 11:00AM CDT
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI), has presented data showing impressive evidence of clinical efficacy from a Phase 2 melanoma clinical trial in a plenary session at the 105 Annual Meeting of the American Association for Cancer Research. The new data confirmed that TIL treatment was associated with a high durable objective response rate in patients with Stage 4 metastatic melanoma, including many who were refractory to checkpoint inhibitors. Lion is working with Dr. Rosenberg under a Cooperative Research and Development Agreement (CRADA) to develop and commercialize this novel TIL therapy.

Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
GlobeNewswire - Mon Mar 24, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.

Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.

Lion Biotechnologies to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5. The conference is being held at The Ritz Carlton in Dana Point, California, from March 9-12, 2014.

Lion Biotechnologies Issues Letter to Shareholders
GlobeNewswire - Mon Feb 03, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., has issued the following letter to the shareholders.

Lion Biotechnologies' CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate's Immunotherapy Forum on January 27
Business Wire - Fri Jan 24, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled "Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies," the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.

Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report
M2 - Mon Jan 20, 9:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/fh839h/the_engineered) has announced the addition of the "Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report" report to their offering. This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. Benefits from the report: - Identify players in the field, from industry and academia; - Find out which TCR technologies are valued by Big Pharma and Biotech; - Understand the value of intracellular antigens targeted by the TCR; - Recognize the challenges of TCR-based therapeutics and their solutions; - Learn which TCR-based therapeutics are attractive for partnering; - Find out which TCR therapeutic approaches are not yet tapped. Key Topics Covered: 1. Executive Summary 2. Introduction 3. The T-Cell Receptor 4. TCR Fusion Proteins 5. TCR-Like (TCRL) Antibodies 6. TCR-Transfected T-Cells 7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells 8. Tumor-Infiltrating Lymphocytes (TILs) 9. Opportunity Analysis for TCR-based Products and Technologies 10. References 11. Corporate R&D Pipelines Companies Mentioned - Adaptimmune - Altor Bioscience - Immunocore - Lion Biotechnologies For more information visit http://www.researchandmarkets.com/research/fh...engineered

Lion Biotechnologies to Present at the Biotech Showcase on January 15
Business Wire - Mon Jan 13, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Singh's presentation will be in Mission Room II.

Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Business Wire - Thu Jan 09, 6:59AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced the appointment of James G. Bender, Ph.D., as Vice President, Product Development and Manufacturing. Dr. Bender has more than 25 years of clinical development experience, primarily focused on cancer therapies, including tumor-infiltrating lymphocytes (TILs).

Lion Biotechnologies to Present at the LD MICRO Conference on December 3
Business Wire - Tue Nov 26, 7:00AM CST
Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00 a.m. Pacific. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.

Lion Biotechnologies Completes $23.3 Million Private Financing
Business Wire - Wed Nov 06, 7:00AM CST
Lion Biotechnologies, Inc. (OTC Markets: LBIO) has completed a previously announced private financing with institutional and other accredited investors for gross proceeds of $23.3 million. After paying the placement agent fees and estimated offering expenses payable by the Company, Lion Biotechnologies received net proceeds of approximately $21.6 million.

Lion Biotechnologies to Raise Approximately $23 Million in Private Financing
Business Wire - Thu Oct 31, 7:00AM CDT
Lion Biotechnologies, Inc. (OTC Markets: LBIO) today announced that it has entered into definitive agreements with institutional and other accredited investors to raise approximately $23 million in a private financing. Subscribers have agreed to purchase units consisting of either (i) one share of common stock and a warrant to purchase a share of common stock, or (ii) one share of the newly authorized Series A Convertible Preferred Stock and a warrant to purchase the number of shares of common stock initially issuable upon the conversion of the preferred stock. The shares of common stock (and accompanying warrants) will be sold at $2.00 per share, and the shares of Series A Convertible Preferred Stock (and accompanying warrants) will be sold at $1,000 per share. The shares of Series A Convertible Preferred Stock will have a stated value of $1,000 per share and will initially be convertible into shares of common stock at a price of $2.00 per share (subject to customary adjustment for stock splits, reorganizations, and similar changes). Each warrant entitles the holder to acquire one share of common stock at a price of $2.50 for a period of five years from the closing.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 141

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 107

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 46

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 17

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 111

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
BBW Lawsuit Puts Guidance and Walmart Claims Under Lens

Updated Category News Views 31

A three-month slice of 2026 has landed Build-A-Bear in the sort of mess investors hate most: a securities complaint centered on whether management's upbeat messaging had already outrun the facts. The lawsuit targets purchases of BBW shares from May 28, 2026 through August 26, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 70

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading

Top 5 Most Recently Viewed Articles

Euroseas Ltd. Achieves Strong Financial Results and Growth

Updated Category News Views 141

Overview of Euroseas Ltd. Euroseas Ltd. operates as a leader in the container shipping sector, primarily focused on providing efficient seaborne transportation for containerized cargo. The company has established a strong reputation for operational excellence and commitment to sustainable practices within its fleet management. Financial Performance Highlights In a recent...

Continue Reading
Market Dynamics Shifting with Focus on Inflation Trends

Updated Category News Views 180

Market Performance and Economic Insights As we dive into today's economic landscape, U.S. stocks have reached new heights while the effects of a recent hurricane are fading. With key inflation data set to be released soon, analysts are closely monitoring market responses and the implications for future Federal Reserve policy. The recent performance of U.S. stocks...

Continue Reading
Strategic Moves: Nordson EVP Acquires Over $250K in Stock

Updated Category News Views 214

Nordson EVP Makes Significant Stock Investment Recently, a notable movement was observed in the stock holdings of Nordson, specifically by its Executive Vice President, Daniel Roy Hopgood. According to a recent SEC filing, Hopgood made a considerable insider purchase worth $251,885, acquiring 1,201 shares of Nordson. Insights into the Insider Transaction This transaction,...

Continue Reading
Rising Pet Poisoning Calls Due to Antidepressants and ADHD Drugs

Updated Category News Views 102

Back between 2019 and 2022, we saw an insane rise in calls to pet poison hotlines—an 84.9% spike related to antidepressants and antianxiety drugs. You know that’s serious business when folks are dialing in about their furry friends getting into the pills meant for human mental health. The numbers don’t lie; as people got more open about mental health issues, it...

Continue Reading
Humacyte, Inc. Investors: Class Action Lawsuit Update

Updated Category News Views 330

Understanding the Class Action Lawsuit Against Humacyte, Inc. Many investors are becoming increasingly aware of the class action lawsuit against Humacyte, Inc. (NASDAQ: HUMA). The firm leading this charge, Pomerantz LLP, has filed this significant case to address potential securities fraud related to the company's operations and communications. This legal action has...

Continue Reading